MedTrace Logo

Avelumab/Gemcitabine in Sarcomatoid RCC

NCT03483883 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-08-26

No results posted yet for this study

Summary

To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

Conditions

  • Metastatic sRCC

Interventions

DRUG

Avelumab

Avelumab IV 10 mg/kg every 2 weeks

DRUG

Gemcitabine

Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Vivek Narayan, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2020-07-22
Completion
2021-02-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03483883 on ClinicalTrials.gov